One of the world's most common livestock diseases is anthrax. Although national initiatives have resulted in anthrax containment globally. According to a study published by the WHO (World Health Organization), it is still prevalent and is largely due to the lack of expertise of the most recent generations of veterinarians in the detection and reporting of the disease, and the discontinuation of vaccination against the disease.            Livestock diseases are leading to a set of problems within livestock production systems. These issues include, declines in production, unstable food security and loss of income, which are adversely affecting human health. Vaccinating animals is one of the livestock disease management for reducing livestock diseases. Among cloven-hoofed animals, such as cattle, swine, sheep, and goats, as well as many species of wild animals the foot-and - mouth disease (FMD) is highly contagious. The increasing occurrence of livestock diseases is therefore a significant driver for veterinary vaccines market.

There is a rising number of people adopting pets in the United States and Canada, and many facilities in major cities of these countries offer adequate pet care services. With increasing urban nature of the societies and more investment in animals as protection of their households as well as enhancing the human-animal relationship are likely to flourish the demand for veterinary vaccines. However, high storage costs for vaccines coupled with shortage of veterinarians and skilled farm workers are hindering the growth of the market.

Advancements in formulations have contributed to the commercialization of modified products, which can be conveniently delivered through the oral route. Improved administration is increasing the acceptance of vaccines for both wild and domestic animals. Companies focus on the development of new vaccines that can combat a wide variety of diseases. MSD animal health, for example, released live poultry vaccines against Newcastle Disease (ND), Marek 's disease (MD), and Infectious Bursal Disease in September 2017.

The global veterinary vaccines market has been segmented based on type, technology, disease and region. Based on type, the veterinary vaccines market is segmented into porcine vaccines, poultry vaccine, livestock vaccine, companion animal vaccine, aquaculture vaccines and other animal vaccines. Porcine vaccines segment dominated the market owing to the high and growing prevalence of disease such as porcine respiratory and reproductive syndrome (PRRS) and porcine epidemic diarrhea.

On the basis of technology, the veterinary vaccines market is segmented into live attenuated vaccines, inactivated vaccines, DNA vaccines, recombinant vaccines, and other vaccines. Live attenuated vaccines segment dominated the market in 2019 as it is the oldest vaccination procedure used in the veterinary sector. For the production of additional applications, this approach is also under trial. Some of these alternatives include the production of intramuscularly provided protein subunit vaccines for swine. These products help lower the mortality rate and increase the lifespan of disease-affected swine. The demand for DNA vaccines is expected to show profitable growth over the forecast period. It has been found that these vaccines are safe and capable of producing responses close to those of live attenuated vaccines. Furthermore, in the presence of high titers of maternal antibodies, DNA vaccines produce performance. Compared to recombinant vaccines and live-attenuated vaccines, DNA vaccines are more stable.

On the basis of disease, the veterinary vaccines market is segmented into porcine, poultry, livestock, companion animal, and aquaculture. Porcine disease dominated the market in 2019 as there are no clinical signs showed when a pig becomes infected for the first time by this disease. Hence, it is most often transmitted easily either by mouth or through the snout, passing into the intestine where it multiplies and subsequently passed out in faeces.

The global veterinary vaccines market is cumulative to North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global veterinary vaccines market in 2019, however Asia Pacific is expected to grow at a highest pace through 2028.

In North America the market growth of veterinary vaccines is projected to be driven by the increased occurrence of canine diseases, the adoption of vaccination for the same combined with the growing population of pets in the U.S.

Europe is the second-largest market for veterinary vaccines after North America. Increasing production of veterinary products, better animal husbandry practices, and higher pet population are propelling the growth of the market in the region.

Asia Pacific is expected to be the fastest growing regional market for veterinary vaccines owing to the increase in livestock populations and government initiatives, especially in developing economies. The market is powered by high R&D spending by many major players, coupled with growing attempts at tolerably low prices to commercialize veterinary pharmaceuticals and inoculations.